Dec 10, 2023 | Jill Zitzewitz, SGL Blogs
Friday was Satellite Symposia Day before the 65th American Society of Hematology Annual Meeting and Exposition (ASH). This day before the kick-off of the official #ASH23 meeting featured many industry-sponsored sessions that provide continuing medical education for...
Dec 9, 2023 | Jack Aiello, SGL Blogs
The Friday before the official start of ASH is always considered Symposium day. Symposiums typically last a couple of hours and involve several myeloma expert doctors discussing patient cases and various treatment options. These meetings are sponsored by advocacy...
Dec 9, 2023 | Barbara Davis, SGL Blogs
Day 0 Blog 2 The second symposium I attended (in sweatpants and fuzzy slippers) was CAR T-cell therapies in relapsed/refractory multiple myeloma: evaluating the evidence for optimal integration, presented by Drs. Sikander Ailawadhi and Ajai Chari. Learn more here. I...
Dec 9, 2023 | Barbara Davis, SGL Blogs
Day 0 Blog 1 First up this morning was “Overcoming racial disparities in multiple myeloma outcomes and clinical trials: how we are moving care forward today.” Learn more here. This very interesting presentation was part of the pre-ASH symposium series for physicians...
Dec 5, 2023 | Michael Tuohy, SGL Blogs
My wife, Robin, and I are grateful to have been attending the annual American Society of Hematology (ASH) meetings with the International Myeloma Foundation (IMF) since the early 2000’s. Time is fleeting, Time is precious, Time is not always on our side. But with...
Dec 5, 2023 | Jill Zitzewitz, SGL Blogs
As I write this blog, I’m sitting in the cancer center, waiting to get my monthly maintenance therapy to keep my myeloma at bay. I’m probably one of the last people at my center who still gets Darzalex (daratumumab) by intravenous (IV) infusion, rather than by...
